Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes of impaired fasting glucose: results from the LIPID trial

Anthony Keech*, David Colquhoun, James Best, Adrienne Kirby, R. John Simes, David Hunt, Wendy Hague, Elaine Beller, Manjula Arulchelvam, Jennifer Baker, Andrew Tonkin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

277 Citations (Scopus)

Abstract

Objective - Diabetes, a major health problem worldwide, increases the risk of cardiovascular disease and its associated mortality. Evidence of the overall benefits of lipid modification in this area is needed. Research design and methods - The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that cholesterol-lowering treatment with pravastatin reduced mortality and coronary heart disease (CHD) events in 9,014 patients aged 31-75 years with CHD and total cholesterol 4.0-7.0 mmol/l. We measured the effects of pravastatin therapy, 40 mg/day over 6.0 years, on the risk of CHD death or nonfatal myocardial infarction and other cardiovascular outcomes in 1,077 LIPID patients with diabetes and 940 patients with impaired fasting glucose (IFG). Results - In patients allocated to placebo, the risk of a major CHD event was 61% higher in patients with diabetes and 23% higher in the IFG group than in patients with normal fasting glucose, and the risk of any cardiovascular event was 37% higher in the diabetic group and 19% higher in the IFG group. Pravastatin therapy reduced the risk of a major CHD event overall from 15.9 to 12.3% (relative risk reduction [RRR] 24%, P < 0.001) and from 23.4 to 19.6% in the diabetic group (19%, P = 0.11); in the diabetic group, the reduction was not significantly different from the reductions in the other groups. Pravastatin reduced the risk of any cardiovascular event from 52.7 to 45.2% (21%, P < 0.008) in patients with diabetes and from 45.7 to 37.1% (26%, P = 0.003) in the IFG group. Pravastatin reduced the risk of stroke from 9.9 to 6.3% in the diabetic group (RRR 39%, CI 7-61%, P = 0.02) and from 5.4 to 3. 4% in the IFG group (RRR 42%, CI -9 to 69%, P = 0.09). Pravastatin did not reduce the incidence of diabetes. Over 6 years, pravastatin therapy prevented one major CHD event (CHD death or nonfatal myocardial infarction) in 23 patients with IFG and 18 patients with diabetes. A meta-analysis of other major trials confirmed the high absolute risks of diabetes and IFG and the absolute benefits of statin therapy in these patients. Conclusions - Cholesterol-lowering treatment with pravastatin therapy prevents cardiovascular events, including stroke, in patients with diabetes or IFG and established CHD.

Original languageEnglish
Pages (from-to)2713-2721
Number of pages9
JournalDiabetes Care
Volume26
Issue number10
DOIs
Publication statusPublished - 1 Oct 2003
Externally publishedYes

Fingerprint Dive into the research topics of 'Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes of impaired fasting glucose: results from the LIPID trial'. Together they form a unique fingerprint.

Cite this